Skip to content

Prospective study of the effects of esketamine on neurofilament light chain protein and cognitive function in elderly patients after thoracoscopic surgery

Prospective study of the effects of esketamine on neurofilament light chain protein and cognitive function in elderly patients after thoracoscopic surgery

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090245
Enrollment
Unknown
Registered
2024-09-26
Start date
2024-09-30
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative cognitive dysfunction

Interventions

Esketamine group:The esketamine group was induced with 0.5mg/kg esketamine and then pumped at 2ug/kg.min until half an hour before the end of surgery.
Placebo group :The placebo group was given equal dose of normal saline at the same time point.

Sponsors

Yancheng Third People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age 65-90. 2.ASA grade I-III. 3. Diagnosis of lung, esophageal, or mediastinal disease. 4. Undergo thoracoscopic surgery, including lobectomy, segmental resection, pulmonary resection, esophagectomy, or mediastinal tumor resection. 5. Single lung ventilation (OLV) under general anesthesia 6. The expected duration of surgery is 2 hours or more. 7. Voluntarily participate in the trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with preoperative cognitive impairment. 2. Patients with a history of long-term use of drugs that affect neuropsychiatric function (hypnotics, anti-anxiety drugs, and antidepressants). 3. Patients with a history of neurological, psychiatric and cardiovascular diseases (such as Alzheimer's disease, cerebral infarction, coronary artery disease, etc.). 4. Patients with severe visual or hearing impairment who cannot be tested for neurocognitive function. 5. Patients with severe liver or kidney damage.

Design outcomes

Primary

MeasureTime frame
Mini-Mental state examination(MMSE) score;NfL;

Secondary

MeasureTime frame
GFAP;IL-6;TNF-a;Mean arterial pressure (MAP) before anesthesia induction (T0), at the beginning of anesthesia (T1), 30 min after anesthesia (T2), and at the end of surgery (T3);Heart rate before anesthesia induction (T0), at the beginning of anesthesia (T1), 30 minutes after anesthesia (T2), and at the end of surgery (T3);Intraoperative opioid consumption;Length of stay in the anesthesia Care Unit (PACU);24h postoperative pain score (VAS);Adverse reactions (vomiting, dizziness, high blood pressure and tachycardia, hallucinations or nightmares);Whether remedial analgesia occurs;

Countries

China

Contacts

Public ContactYuanyuan Gao

Yancheng Third People's Hospital

13770164821@163.com+86 137 7016 4821

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026